Post-marketing safety signals of the ROCK2 inhibitor Belumosudil for chronic graft-versus-host disease: a real-world disproportionality analysis based on the FAERS database

Objective To characterize the real-world post-marketing safety profile, evidence hierarchy, and demographic vulnerabilities of the selective ROCK2 inhibitor Belumosudil in chronic graft-versus-host disease (cGVHD) using FAERS. Methods Adverse event reports (Q3 2021–Q4 2025) were extracted from FAERS. To control indication confounding, primary disproportionality analysis was anchored to a disease-restricted cGVHD and hematopoietic stem cell transplantation background ( n = 921 , 529 ) using four consensus algorithms (ROR, PRR, BCPNN, MGPS) with False Discovery Rate (FDR) validation. Signals were filtered via a prespecified clinical protocol and stratified into a three-tier evidence framework. Subgroup vulnerabilities (prognostic mortality, age, sex) were evaluated using Fisher’s exact tests. Dual sensitivity analyses evaluated polypharmacy (monotherapy cohort with standardized mean difference [SMD] balance) and denominator stability (whole-database comparator). Results Among 1,797 primary suspect Belumosudil reports (6,056 adverse events), initial screening identified 61 consensus-positive Preferred Terms (PTs); 60 maintained FDR significance ( q < 0.05 ). After systematically excluding 16 confounded administrative and indication-synonymous terms, 45 core PTs were retained across three tiers (Tier 1 trial verification, n = 6 ; Tier 2 novel mechanistic signals, n = 6 ; Tier 3 clinical confounders, n = 33 ). Pharmacological toxicities clustered into three dimensions: musculoskeletal symptoms (muscle tightness, ROR = 10.25; skin swelling, ROR = 19.32), mucosal/viral infections (respiratory syncytial virus, ROR = 4.02; viral gastroenteritis, ROR = 4.81), and laboratory abnormalities (hepatic enzyme increased, ROR = 5.64; blood immunoglobulin G decreased, ROR = 5.75). Subgroup stratification identified distinct clinical vulnerabilities: fatal cases were enriched for obliterative bronchiolitis and muscle atrophy; elderly patients ( ≥ 65 years) exhibited predilection for joint stiffness and lip pain ( P < 0.05 ); and females displayed heightened susceptibility to transaminase elevation, skin atrophy, and oral mucosal blistering ( P < 0.05 ). Monotherapy sensitivity analysis ( N = 1 , 255 ; almost all baseline SMDs < 0.10 ) and whole-database comparison confirmed signal robustness. Conclusion Belumosudil’s real-world safety landscape is dominated by musculoskeletal tightness and edema, mucosal and viral infections, and transaminase/immunoglobulin fluctuations, without novel systemic organ toxicities. Findings underscore the necessity of tailored clinical surveillance: monitoring pulmonary decline in severe disease, joint stiffness in elderly recipients, and hepatic transaminases in females.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1884204
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-marketing safety signals of the ROCK2 inhibitor Belumosudil for chronic graft-versus-host disease: a real-world disproportionality analysis based on the FAERS database

Yulan Zeng, Tao� Zhang, Junguo Duan, Xiyue Tan et al.
6 links
Frontiers in Immunology
Pharmacovigilance and Adverse Drug Reactions
article

Post-marketing safety signals of the ROCK2 inhibitor Belumosudil for chronic graft-versus-host disease: a real-world disproportionality analysis based on the FAERS database

Yulan Zeng, Tao� Zhang, Junguo Duan, Xiyue Tan, Ruixia Wang, Yuxia Liu, Hao Wu, Fei Wang, Xueting Wang
article en

Abstract

Objective To characterize the real-world post-marketing safety profile, evidence hierarchy, and demographic vulnerabilities of the selective ROCK2 inhibitor Belumosudil in chronic graft-versus-host disease (cGVHD) using FAERS. Methods Adverse event reports (Q3 2021–Q4 2025) were extracted from FAERS. To control indication confounding, primary disproportionality analysis was anchored to a disease-restricted cGVHD and hematopoietic stem cell transplantation background ( n = 921 , 529 ) using four consensus algorithms (ROR, PRR, BCPNN, MGPS) with False Discovery Rate (FDR) validation. Signals were filtered via a prespecified clinical protocol and stratified into a three-tier evidence framework. Subgroup vulnerabilities (prognostic mortality, age, sex) were evaluated using Fisher’s exact tests. Dual sensitivity analyses evaluated polypharmacy (monotherapy cohort with standardized mean difference [SMD] balance) and denominator stability (whole-database comparator). Results Among 1,797 primary suspect Belumosudil reports (6,056 adverse events), initial screening identified 61 consensus-positive Preferred Terms (PTs); 60 maintained FDR significance ( q < 0.05 ). After systematically excluding 16 confounded administrative and indication-synonymous terms, 45 core PTs were retained across three tiers (Tier 1 trial verification, n = 6 ; Tier 2 novel mechanistic signals, n = 6 ; Tier 3 clinical confounders, n = 33 ). Pharmacological toxicities clustered into three dimensions: musculoskeletal symptoms (muscle tightness, ROR = 10.25; skin swelling, ROR = 19.32), mucosal/viral infections (respiratory syncytial virus, ROR = 4.02; viral gastroenteritis, ROR = 4.81), and laboratory abnormalities (hepatic enzyme increased, ROR = 5.64; blood immunoglobulin G decreased, ROR = 5.75). Subgroup stratification identified distinct clinical vulnerabilities: fatal cases were enriched for obliterative bronchiolitis and muscle atrophy; elderly patients ( ≥ 65 years) exhibited predilection for joint stiffness and lip pain ( P < 0.05 ); and females displayed heightened susceptibility to transaminase elevation, skin atrophy, and oral mucosal blistering ( P < 0.05 ). Monotherapy sensitivity analysis ( N = 1 , 255 ; almost all baseline SMDs < 0.10 ) and whole-database comparison confirmed signal robustness. Conclusion Belumosudil’s real-world safety landscape is dominated by musculoskeletal tightness and edema, mucosal and viral infections, and transaminase/immunoglobulin fluctuations, without novel systemic organ toxicities. Findings underscore the necessity of tailored clinical surveillance: monitoring pulmonary decline in severe disease, joint stiffness in elderly recipients, and hepatic transaminases in females.

Frontiers in ImmunologyVol. 17
Chengdu University (CN), Chengdu University of Traditional Chinese Medicine (CN)
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon